Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration

Aim: Providing intravitreal ranibizumab therapy for neovascular age related macular degeneration (nARMD) is a source of increasing strain for many UK eye departments. Whilst most units attempt to adhere to the product licence of following up patients at four weekly intervals; delays in follow up app...

Full description

Bibliographic Details
Main Authors: Gwyn Samuel Williams, Eulee Seow, Huw Evans, Muyiwa Owoniyi, Sam Evans, Christopher Blyth
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-07-01
Series:Saudi Journal of Ophthalmology
Online Access:http://www.sciencedirect.com/science/article/pii/S1319453415000296